Puma Biotechnology

411 articles about Puma Biotechnology

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - November 06, 2023

  11/6/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 15,000 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology Reports Third Quarter 2023 Financial Results

  11/2/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023.

• Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

  10/19/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, November 2, 2023, following the release of its third quarter 2023 financial results.

• Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

  10/14/2023

  Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2023

  10/4/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

  9/21/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A, for the treatment of patients with small cell lung cancer (SCLC).

• Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  8/31/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the “Company”), announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the hybrid H.C. Wainwright 25th Annual Global Investment Conference, which will be held September 11-13, 2023.

• Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

  8/8/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Puma can proceed with the clinical development of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (SCLC).

• Puma Biotechnology Reports Second Quarter 2023 Financial Results

  8/3/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023.

• Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results

  7/20/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 3, 2023, following the release of its second quarter 2023 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 06, 2023

  6/6/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

  6/4/2023

  Puma Biotechnology, Inc. announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic hormone receptor positive and triple negative breast cancer at the 2023 American Society of Clinical Oncology Annual Meeting held June 2-6 in Chicago and online.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology Reports First Quarter Financial Results

  5/4/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023.

• Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results

  4/20/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 11, 2023

  4/11/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 8, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 22,000 shares of Puma common stock to four new non-executive employees.

• Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology

  3/14/2023

  Puma Biotechnology, Inc. announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 03, 2023

  3/3/2023

  Puma Biotechnology, Inc. announced that on March 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 9,375 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results

  3/2/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022.

• Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference

  2/28/2023

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend Cowen’s 43rd Annual Health Care Conference, which will be held March 6 – 8, 2023 at the Boston Marriott Copley Place in Boston.